Which are the causes of Cloves Syndrome?

CLOVES syndrome is caused by post-zygotic somatic gain-of-function mutations in the PIK3CA gene, which occur after conception rather than being inherited from parents. These mutations trigger the overactivation of the PI3K/AKT/mTOR signaling pathway, leading to the characteristic overgrowth of fatty tissues, blood vessels, and skeletal structures seen in patients.

What causes CLOVES syndrome at the genetic level?

The primary cause of CLOVES syndrome is a sporadic mutation in the PIK3CA gene. Unlike many genetic conditions, this mutation is not passed down from parents; it occurs randomly in a single cell during early embryonic development. Because this is a somatic mosaic condition, only a portion of the body's cells carry the mutation, while others remain genetically normal. This explains why the clinical presentation of CLOVES syndrome varies so significantly between different individuals.

How does the PIK3CA mutation affect the body?

The PIK3CA gene provides instructions for making a protein that acts like a "gas pedal" for cell growth and division. In CLOVES syndrome, the mutated protein is stuck in the "on" position, causing cells to grow and multiply uncontrollably. This overactive signaling pathway results in the hallmark features of the syndrome, which include:

• Congenital Lipomatous Overgrowth


• Vascular malformations


• Epidermal nevi


• Spinal/skeletal anomalies

Are there environmental triggers for CLOVES syndrome?

Currently, there is no evidence that environmental factors, toxins, or parental lifestyle choices contribute to the development of CLOVES syndrome. The mutation occurs by chance after fertilization. It is important for caregivers to know that nothing done during pregnancy causes the disease, and it cannot be prevented by any known external intervention.

What is the current state of research into the etiology?

Medical researchers are actively investigating targeted therapies, such as PI3K inhibitors, to "throttle back" the overactive signaling pathway that drives CLOVES syndrome. Ongoing studies focus on better understanding the mosaic distribution of the mutation and how it influences the severity of vascular and skeletal overgrowth.

Next steps

• Consult with a geneticist to confirm the diagnosis via targeted tissue biopsy or specialized genetic testing.


• Connect with the 7 members of the DiseaseMaps.org community who have shared their experiences with CLOVES syndrome.


• Discuss potential clinical trials involving PI3K-pathway inhibitors with your specialist physician.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of a qualified healthcare provider.

References

• NIH Genetic and Rare Diseases Information Center (GARD): CLOVES syndrome.


• Orphanet: PIK3CA-related overgrowth spectrum (PROS).


• OMIM (Online Mendelian Inheritance in Man): Entry #612918.


• The CLOVES Syndrome Community: Patient-led research and support resources.